Innovent Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Progress
We are confident that Innovent is well positioned to sustain its rapid growth and deliver tremendous value for our patients and shareholders."
- We are confident that Innovent is well positioned to sustain its rapid growth and deliver tremendous value for our patients and shareholders."
- Presented key results from 6 clinical studies of Tyvyt either orally or by posters/abstracts at ASCO in 2019.
- Innovent will host a live conference call at 9:00 a.m. March 31, 2020 Beijing time to review its financial results and provide a general corporate progress.
- Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts.